In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Justin A. Clark, Brandon Kulengowski, David S. Burgess

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66–0.87]; however, the MIC90 observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.

Original languageEnglish
Article number106178
JournalInternational Journal of Antimicrobial Agents
Volume56
Issue number6
DOIs
StatePublished - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy

Keywords

  • Antimicrobial susceptibility testing
  • CRE
  • Carbapenem-resistant Enterobacteriaceae
  • Eravacycline
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this